Literature DB >> 30368624

Contemporary treatment of metastatic renal cell carcinoma.

Pawel Wiechno1, Jakub Kucharz2, Malgorzata Sadowska1, Wojciech Michalski1, Bozena Sikora-Kupis1, Joanna Jonska-Gmyrek1, Grazyna Poniatowska1, Karol Nietupski1, Krzysztof Ossolinski3, Tomasz Demkow1.   

Abstract

Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20-30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that-with the introduction of new drugs-the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.

Entities:  

Keywords:  Immunotherapy; Renal cell carcinoma; Targeted therapy

Mesh:

Year:  2018        PMID: 30368624     DOI: 10.1007/s12032-018-1217-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  61 in total

1.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

Authors:  George V Thomas; Chris Tran; Ingo K Mellinghoff; Derek S Welsbie; Emily Chan; Barbara Fueger; Johannes Czernin; Charles L Sawyers
Journal:  Nat Med       Date:  2005-12-11       Impact factor: 53.440

2.  Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.

Authors:  Arkadiusz Z Dudek; Ahmad Raza; Ming Chi; Meghali Singhal; Rajneet Oberoi; Rajendar K Mittapalli; Sagar Agarwal; William F Elmquist
Journal:  Clin Genitourin Cancer       Date:  2012-12-21       Impact factor: 2.872

3.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

4.  Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.

Authors:  Kriti Mittal; Henry Koon; Paul Elson; Pierre Triozzi; Afshin Dowlati; Helen Chen; Ernest C Borden; Brian I Rini
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

Review 5.  Renal cell carcinoma: resection of solitary and multiple metastases.

Authors:  H W Pogrebniak; G Haas; W M Linehan; S A Rosenberg; H I Pass
Journal:  Ann Thorac Surg       Date:  1992-07       Impact factor: 4.330

6.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

Review 7.  Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Authors:  Emiliano Calvo; Manuela Schmidinger; Daniel Y C Heng; Viktor Grünwald; Bernard Escudier
Journal:  Cancer Treat Rev       Date:  2016-09-10       Impact factor: 12.111

8.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Authors:  Robert J Motzer; Naomi B Haas; Frede Donskov; Marine Gross-Goupil; Sergei Varlamov; Evgeny Kopyltsov; Jae Lyun Lee; Bohuslav Melichar; Brian I Rini; Toni K Choueiri; Milada Zemanova; Lori A Wood; M Neil Reaume; Arnulf Stenzl; Simon Chowdhury; Ho Yeong Lim; Ray McDermott; Agnieszka Michael; Weichao Bao; Marlene J Carrasco-Alfonso; Paola Aimone; Maurizio Voi; Christian Doehn; Paul Russo; Cora N Sternberg
Journal:  J Clin Oncol       Date:  2017-09-13       Impact factor: 44.544

9.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

Review 10.  Treatment options for metastatic renal cell carcinoma: a review.

Authors:  Uzma Athar; Teresa C Gentile
Journal:  Can J Urol       Date:  2008-04       Impact factor: 1.344

View more
  15 in total

1.  NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation.

Authors:  Jiatian Lin; Xiangling Chen; Hongjian Yu; Shasha Min; Yequn Chen; Zesong Li; Xina Xie
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

Review 2.  Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma.

Authors:  Bryce R Christensen; Yasmin M Hajja; Vadim Koshkin; Pedro C Barata
Journal:  Curr Treat Options Oncol       Date:  2021-01-12

3.  UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.

Authors:  Peng Hao; Bo Kang; Yapeng Li; Wenqi Hao; Feihong Ma
Journal:  Mol Med Rep       Date:  2019-06-03       Impact factor: 2.952

4.  Solitary Metastasis in the Mediastinal Lymph Node After Radical Nephrectomy for Clear Cell Renal Cell Carcinoma: A Case Report and Literature Review.

Authors:  Hang Lin; Heng Zhang; Yuanda Cheng; Chunfang Zhang
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

5.  Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway.

Authors:  Yadong Liu; Huiyan Lv; Xingyi Li; Jiannan Liu; Song Chen; Yaodong Chen; Yinshan Jin; Ruihua An; Shiliang Yu; Zhigang Wang
Journal:  Int J Biol Sci       Date:  2021-08-13       Impact factor: 6.580

6.  Immunological perspective on the malignant progression of renal clear cell carcinoma.

Authors:  Ji Liu; Wentao Zhang; Kang Lin; Wenchao Ma; Wei Li; Xudong Yao
Journal:  Ann Transl Med       Date:  2021-10

7.  Clinical Study on the Efficacy of Microwave Ablation (MA) in the Treatment of Stage I Renal Clear Cell Carcinoma by CT and MRI Imaging.

Authors:  Jiang Zhu; Si Chen; Yanchen Wang; TongBin Gao; Yongjian Ji; Shenyang Wang
Journal:  J Healthc Eng       Date:  2022-02-07       Impact factor: 2.682

8.  Initial Presentation of Renal Cell Carcinoma as Heart Failure Secondary to Tumor-Thrombus Extension to the Right Atrium.

Authors:  Keshav R Patel; Dilpat Kumar; Jagadeesh K Kalavakunta; Fnu Warsha
Journal:  Cureus       Date:  2021-04-17

9.  Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma.

Authors:  Yuanyuan Guo; Beibei Liu; Yihan Liu; Wei Sun; Wuyue Gao; Shilong Mao; Li Chen
Journal:  Front Cell Dev Biol       Date:  2021-06-29

10.  Tumor-Educated Platelets as a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma.

Authors:  Ruotao Xiao; Cheng Liu; Bo Zhang; Lulin Ma
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.